Coronavirus Notebook: ‘No Urgent Need’ For Booster Vaccines, But EU & UK Advise Additional Doses In Immunocompromised
Executive Summary
ExeVir Bio has begun a Phase Ib study of its neutralizing antibody XVR011, NRx Pharmaceuticals has reported promising results with aviptadil in improving lung function, and Meletios Therapeutics has raised funds to further the development of an antiviral that acts on the SARS-CoV-2 virus and infected host cells.
You may also be interested in...
Coronavirus Notebook: Sanofi Under Pressure To Hand mRNA Vaccine To Africa, EMA OKs Booster Dose For Comirnaty
The European Medicines Agency says there is a possible link between the Janssen vaccine and rare cases of venous thromboembolism, and that immune thrombocytopenia should be added as an adverse reaction to the Janssen and AstraZeneca vaccines. The agency has also begun evaluating a marketing authorization application for Celltrion’s regdanvimab in COVID-19 patients.
Coronavirus Notebook: WHO Backs MAb Combo, EMA Assessing Moderna Booster Jab
The COVID Moonshot project has received new funding for the open-source development of new candidate therapeutics, with results expected by the end of the year.
COVID-19: EU Assessing Booster Dose Of Pfizer/BioNTech’s Comirnaty
As the debate continues over whether booster vaccines will be required to sustain waning immune responses in the general population, the EU regulator says it should have the results of its assessment of an application for a booster dose of Cominarty in the next few weeks.